Evidence map›Paper›PMID 34427579›Full record

Observational studyRheumatology (Oxford, England)2022

Identifying trajectories of radiographic spinal disease in ankylosing spondylitis: a 15-year follow-up study of the PSOAS cohort.

Mark C Hwang, MinJae Lee, Lianne S Gensler, Matthew A Brown, Amirali Tahanan, Mohammad H Rahbar, Theresa Hunter, Mingyan Shan, Mariko L Ishimori, John D Reveille and 2 more

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Rheumatology (Oxford, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Axial Imaging in Spondyloarthritis.Rheumatic diseases clinics of North America · 2024
    Review
  3. Review
  4. Article
  5. A glance into the future of diagnosis and treatment of spondyloarthritis.Therapeutic advances in musculoskeletal disease · 2022
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Mark C HwangDepartment of Internal Medicine, Division of Rheumatology, John P. and Katherine G. McGovern School of Medicine at the University of Texas Health Science Center at Houston, Houston.ORCID 0000-0003-2160-1481
MinJae LeeDepartment of Population & Data Sciences, Division of Biostatistics, University of Texas Southwestern Medical Center, Dallas.
Lianne S GenslerDepartment of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-6314-5336
Matthew A BrownInstitute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Princess Alexandra Hospital, Queensland, Australia.ORCID 0000-0003-0538-8211
Amirali TahananDepartment of Internal Medicine, Division of Clinical and Translational Sciences, John P. and Katherine G. McGovern School of Medicine at the University of Texas Health Science Center at Houston, Houston, TX.
Mohammad H RahbarDepartment of Internal Medicine, Division of Clinical and Translational Sciences, John P. and Katherine G. McGovern School of Medicine at the University of Texas Health Science Center at Houston, Houston, TX.
Theresa HunterEli Lilly and Company, Indianapolis, IN.
Mingyan ShanEli Lilly and Company, Indianapolis, IN.
Mariko L IshimoriDepartment of Medicine-Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-0421-8854
John D ReveilleDepartment of Internal Medicine, Division of Rheumatology, John P. and Katherine G. McGovern School of Medicine at the University of Texas Health Science Center at Houston, Houston.ORCID 0000-0001-5950-0913
Michael H WeismanDepartment of Medicine-Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0001-5568-388X
Thomas J LearchDepartment of Medicine-Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA, USA.
Cedars-Sinai Medical Center · USEli Lilly (United States) · USThe University of Texas Southwestern Medical Center · USTranslational Research Institute · AUUniversity of California, San Francisco · US

Funding

Institutional Career Development CoreKL2TR003168 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MILLER, CHARLES C · 2019 to 2023
$4.9M
NCATS NIH HHS KL2 TR003168
6 · The paper itself

Abstract

objectivesLittle is known with certainty about the natural history of spinal disease progression in ankylosing spondylitis (AS). Our objective was to discover if there were distinct patterns of change in vertebral involvement over time and to study associated clinical factors.

methodsData were analysed from the Prospective Study of Outcomes in Ankylosing Spondylitis (PSOAS) observational cohort. All patients met modified New York Criteria for AS and had ≥2 sets of radiographs scored by modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) by two independent readers between 2002 and 2017. Group-based trajectory modelling (GBTM) was used to classify patients into distinct groups of longitudinal mSASSS considering sociodemographic and clinical covariables. The optimal trajectory model and number of trajectories was selected using Nagin's Bayesian information criterion (BIC).

resultsA total of 561 patients with 1618 radiographs were analysed. The optimum number of trajectory groups identified was four (BIC -4062). These groups were subsequently categorized as: non-progressors (204 patients), late-progressors (147 patients), early-progressors (107 patients) and rapid-progressors (103 patients). Baseline predictors associated with higher spinal disease burden groups included: baseline mSASSS, male gender, longer disease duration, elevated CRP and smoking history. In addition, time-varying anti-TNF use per year was associated with decreased mSASSS progression only in the rapid-progressor group.

conclusionsGBTM identified four distinct patterns of spinal disease progression in the PSOAS cohort. Male gender, longer disease duration, elevated CRP and smoking were associated with higher spinal disease groups. Independent confirmation in other AS cohorts is needed to confirm these radiographic patterns.

Indexed as

Spondylitis, AnkylosingBayes TheoremDisease ProgressionFollow-Up StudiesHumansMaleProspective StudiesSeverity of Illness IndexSpineTumor Necrosis Factor InhibitorsTumor Necrosis Factor Inhibitorsankylosing spondylitislongitudinal modeling

Identifiers

PMID34427579
PMCPMC9071538
OpenAlexW3193409001

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.